Source comparison
Telehealth Clinicians Tesamorelin Protocol: Treatment Comparison
Starting Dose 2 mg SC daily 1 mg SC daily 2 mg SC 5 days/week Standard protocol delivers 12–18% VAT reduction in responders; maintenance prevents rebound; cycling addresses desensitization IGF-1 Monitoring Baseline, weeks 8/16/24 Every 12 weeks Baseline, weeks
This comparison does not assign a generated winner or score.
- Starting Dose
- 2 mg SC daily
- 1 mg SC daily
- 2 mg SC 5 days/week
- Standard protocol delivers 12–18% VAT reduction in responders; maintenance prevents rebound; cycling addresses desensitization
- IGF-1 Monitoring
- Baseline, weeks 8/16/24
- Every 12 weeks
- Baseline, weeks 8/20
- Monitoring frequency must match dose intensity. Maintenance requires less frequent checks
- Glucose Monitoring
- Fasting glucose at weeks 4/8/12/16
- HbA1c every 6 months
- Fasting glucose at weeks 4/12/20
- Glucose dysregulation risk scales with dose and IGF-1 elevation. Tighter monitoring at higher doses
- VAT Reduction Target
- 15–20% from baseline
- Prevent rebound (maintain reduction)
- 18–22% (higher ceiling due to cycling)
- Cycling may push past standard plateau if initiated at week 16–20
- Duration
- 26 weeks, then reassess
- Ongoing (patients typically continue 12–24 months)
- 26–40 weeks
- Longer durations require cost-benefit analysis. VAT reduction plateaus but doesn't reverse while on therapy
- Adverse Event Rate
- Injection site reactions 35%, arthralgia 15%
- Lower (10–12% joint pain at 1 mg)
- Similar to standard protocol
- Dose reduction at maintenance significantly lowers AE burden without full VAT rebound